---------- Forwarded message ----------
From: "IRIN" <[email protected]>
Date: 23 Dec 2013 17:54
Subject: Life-saving hepatitis C drug approved, but cost is high
To: "Elisabeth Janaina" <[email protected]>
[image: IRINnews logo] <http://www.irinnews.org/>
humanitarian news and analysis
a service of the UN Office for the Coordination of Humanitarian Affairs
*Life-saving hepatitis C drug approved, but cost is high
<http://www.irinnews.org/report.aspx?reportid=99381>*
[image: lead photo]NEW YORK, 23 December 2013 (IRIN) - Following approvals
in the US and Europe this month of a new drug to treat hepatitis C,
activists are pushing for the medication to be made available in poor
countries, a development reminiscent of the activism that forced down
HIV/AIDS drug prices a decade ago in Brazil, South Africa and Thailand.
The World Health Organization (WHO) estimates that as many as 185 million
people are infected with hepatitis C, which is often called a “viral time
bomb” because it can exist, undiagnosed, in a person’s body for many years
without causing symptoms.
According to the Open Society
Foundations<http://www.opensocietyfoundations.org/publications/beyond-hype-what-sofosbuvir-means-and-doesn-t-global-hepatitis-c-treatment%20>(OSF),
more than 350,000 people die every year from liver disease related
to the virus, and every year an estimated three to four million more people
are infected.
Many of these people are co-infected with HIV; the illnesses are both
blood-borne and have shared routes of transmission, particularly injecting
drug use.
Unlike HIV, hepatitis C can be cured. But current treatment options have
serious side effects, do not always work and are unaffordable for most
people. The existing treatment, pegylated interferon, which is manufactured
by Roche and Merck, can cost as much as US$18,000 for a 48-week course.
Interferon, which must be injected, can, in combination with the drug
ribavirin, cure 40-70 percent of patients who use it. But its high cost has
kept it out of reach for most patients, except in Egypt and Thailand, where
the governments were able to negotiate significant price reductions with
drug manufacturers.
The new drug, sofosbuvir, released by pharmaceutical giant Gilead, promises
a leap forward in the hepatitis C treatment. It is orally administered,
reduces treatment time to 12 weeks, has fewer side effects, and, if used in
combination with other drugs, can achieve a 90 percent cure rate. The
hitch? The price tag.
In the US, which has some of the highest drug prices
<http://www.ncbi.nlm.nih.gov/pubmed/23569056%20>in the world, Gilead is
expected to charge $80,000 for one course of treatment - more than four
times the cost of interferon. While the cost of the drug is likely to be
lower elsewhere, healthcare advocates fear the price will remain beyond the
reach of poor people.
*Pricing*
Médicins Sans Frontières’ director of policy and analysis, Rohit Malpani,
says the drug has been priced so high because it cost the company $11
billion to acquire Pharmasset, the original maker of the drug.
According to one analyst, Gilead has to make $4 billion on the drug
annually<http://dealbook.nytimes.com/2011/11/21/gilead-to-buy-pharmasset-for-11-billion>,
to justify the high cost of the buyout.
This is not a reflection of the research and development costs; it is an
assessment of how much the company can get for it, Malpani adds. “Companies
will engage in extensive studies to determine what the market will bear,
but that is not the way that life-saving commodities should be priced.”
*Access strategy*
MSF’s Access Campaign, which lobbies for affordable medicines for
resource-strapped communities, is waiting for Gilead to finalize its
“access strategy” for poor countries after having received input from a
range of organizations.
A Gilead spokesperson told IRIN that it would announce the details of its
access programme early next year. The company says it is “committed to
making its medicines available to patients, regardless of where they live
or their ability to pay”, and that it is “working very closely with
advocates in communities that are affected by hepatitis C to develop an
appropriate access and pricing strategy”.
The spokesperson said Gilead wanted to “help ensure access to Sovaldi [the
brand name for sofosbuvir] in resource-limited countries, especially
countries that have a high hepatitis C burden”.
However, Malpani is not optimistic that the reduced price will be low
enough to make the drug widely accessible. Furthermore, MSF believes Gilead
is likely to offer “middle-income” countries - like China, Iran and Ukraine
- a higher pricing strategy than that given to poor countries.
Ironically, 75 percent of the world’s poor reside in middle-income
countries, Malpani said. “Our concern with Gilead’s access strategy is that
it is likely to be unaffordable and punitive to the countries in that
category,” he said.
MSF would like to set a target price for the drug of less than $500.
However, according to an OSF report, "Unfortunately, past experience with
HIV suggests that drug companies are unlikely to voluntarily extend
significant discounts to middle-income countries, even if they may be open
to reducing the price for the world's poorest."
According to one study <http://freepdfhosting.com/d4a7e2bba6.pdf%20>, a
12-week course of sofosbovir could cost as little as $62-$134 to produce.
Asked why the drug was so expensive in the US, the Gilead spokesperson
said: “We believe that the price of Sovaldi in the United States is fair,
based on the value it represents to a larger number of patients.” A special
programme for those unable to afford it would be available, he added.
“But the starting point is so outrageous, not even halving it would make it
accessible,” says Els Torreele, director of OSF’s Access to Essential
Medicines Initiative.
“How have we got to a global system where new drugs being developed are out
of reach of most of the population? It’s totally normal today to price
drugs at $100,000. Something is wrong with a system where drugs that so
many people need are costing so much. This is not sustainable for anyone,”
she said.
Daniel Wolfe, director of the International Harm Reduction Development
Program at OSF, said that because of its association with HIV and drug use,
hepatitis C is still highly stigmatized. “The experience of HIV has shown
us that the combination of expensive medication and social stigma is
deadly,” he said.
He added that companies are pricing their drugs for profit rather than
public health concerns. “When governments are confronted by high prices for
a stigmatized population affected, they tend to look the other way,” Wolfe
said.
*Patent worries*
In India a “patent opposition” has been filed by the Initiative for
Medicines Access and Knowledge (I-MAK) to stop Gilead from obtaining
<http://www.msfaccess.org/about-us/media-room/press-releases/gilead-attempt-secure-patent-hepatitis-c-drug-opposed-india%20>a
patent on the drug there, which would clear the way for low-cost generics
to be manufactured.
India has long been at the forefront of manufacturing generic life-saving
drugs. Under its Patent Act, medications that are not new do not qualify
for patent protection; I-Mak argues that sofosbuvir is “old science”
stemming from a long line of antiretroviral drugs.
The World Trade Organization’s 1995 Trade-related Aspects of Intellectual
Property Rights (TRIPS) agreement laid down minimum standards for patent
laws. There is, however, “some flexibility for countries to determine what
is meant under the criteria of patentability”, says Torreele, citing
I-MAK’s case against Gilead’s sofosbuvir patent.
Since social activism
<http://www.opensocietyfoundations.org/voices/end-hepatitis-c-patients-must-come-profits%20>helped
force down the cost of AIDS drugs with generic alternatives over a decade
ago, “the world has changed,” says Torreele. “The solutions to making HIV
drugs affordable are not there anymore.”
While TRIPS makes allowances for governments to override patent laws to
protect public health, “there is lots of pressure by the pharmaceutical
industry on them to avoid these measures”.
And
negotiations<http://www.theguardian.com/world/2013/dec/10/trans-pacific-partnership-a-guide-to-the-most-contentious-issues%20>,
spearheaded by the US, are currently taking place with 11 other countries
to finalize the Transpacific Partnership Agreement, a trade deal that some
worry could undermine the flexibility allowed by TRIPS.
pg/rz
Read report online <http://www.irinnews.org/report.aspx?reportid=99381>
------------------------------
[This report does not necessarily reflect the views of the United
Nations]
Feedback <http://www.irinnews.org/websitefeedback.aspx> | Terms &
Conditions <http://www.irinnews.org/copyright.aspx> | [image: RSS feeds] News
Feeds <http://www.irinnews.org/RSS.aspx> | About
IRIN<http://www.irinnews.org/about.aspx>
| Jobs <http://www.irinnews.org/jobs.aspx> |
Donors<http://www.irinnews.org/donors.aspx>
Copyright © IRIN 2013. All rights reserved. This material comes to you via
IRIN, the humanitarian news and analysis service of the UN Office for the
Coordination of Humanitarian Affairs. The opinions expressed do not
necessarily reflect those of the United Nations or its Member States. The
boundaries, names and designations used on maps on this site and links to
external sites do not imply official endorsement or acceptance by the UN.
Republication is subject to terms and conditions as set out in the IRIN
copyright page <http://www.irinnews.org/copyright.aspx>.
IRIN Arabic for mobile: http://m.irinnews.org/ar/<http://m.irinnews.org/ar/>
--
You received this message because you are subscribed to the Google Groups
"South Sudan Info - The Kob" group.
To unsubscribe from this group and stop receiving emails from it, send an email
to [email protected].
To post to this group, send email to [email protected].
To view this discussion on the web visit
https://groups.google.com/d/msgid/SouthSudanKob/CAJb14oq5AkAjg1gQHVLtkz4-29HQ4ViTsvrG-v1azUgxLCL4dg%40mail.gmail.com.
For more options, visit https://groups.google.com/groups/opt_out.
